Oramed Pharmaceuticals Inc.
NASDAQ:ORMPBiotechnology
+$0.03 today
- Market cap
- $160.46M
- Beta
- 1.24
- P/E (TTM)
- 1.4
- EPS (TTM)
- $2.70
- Dividend yield
- 6.54%
Volume 0.27M
Average 0.16M
Balance Sheet
Inspect the capital base behind the business.
Assets
$230.86M
FY 2025 · Annual
+48.7% YoYLiabilities
$31.12M
FY 2025 · Annual
+213.4% YoYEquity
$199.74M
FY 2025 · Annual
+37.4% YoYBalance Sheet
Metric | FY2021 Aug 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 77.25M | 40.46M | 9.06M | 54.42M | 45.95M |
| Short-term Investments | 16.9M | 115.26M | 152.99M | 87.51M | 79.95M |
| Net Receivables | 0 | 0 | 0 | 0 | 4.64M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.2M | 1.39M | 537K | 1.29M | 2.74M |
| Total Current Assets | 95.34M | 157.11M | 162.58M | 143.22M | 133.27M |
| Property, Plant & Equipment (Net) | 932K | 1.81M | 1.57M | 1.11M | 1.34M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 6.69M | 2.7M | 56.37M | 10.91M | 93.74M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 25.04M | 24K | 34K | 34K | 2.52M |
| Total Non-current Assets | 32.66M | 4.53M | 57.97M | 12.06M | 97.59M |
| Total Assets | 128M | 161.64M | 220.55M | 155.28M | 230.86M |
| Account Payables | 2.61M | 2.18M | 551K | 789K | 443K |
| Short-term Debt | 130K | 247K | 51.01M | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 3.2M | 0 |
| Deferred Revenue | 2.7M | 1.34M | 0 | 0 | 1.35M |
| Other Current Liabilities | (1.37M) | (191K) | 325K | 1.07M | 2.37M |
| Total Current Liabilities | 6.68M | 5.75M | 53.21M | 5.69M | 19.09M |
| Long-term Debt | 403K | 647K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 11K | 11K | 0 | 0 | 7.91M |
| Deferred Revenue (Non-current) | 4.24M | 4M | 4M | 4M | 3.27M |
| Other Non-current Liabilities | 145K | 82K | 102K | 90K | 314K |
| Total Non-current Liabilities | 4.8M | 4.74M | 4.44M | 4.25M | 12.03M |
| Total Liabilities | 11.48M | 10.49M | 57.66M | 9.93M | 31.12M |
| Common Stock | 424K | 476K | 485K | 480K | 472K |
| Retained Earnings | (114.85M) | (163.08M) | (157.56M) | (176.62M) | (123.44M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 230.2M | 314.42M | 0 | 0 | 0 |
| Minority Interest | 744K | (656K) | (928K) | (918K) | 0 |
| Total Equity | 116.52M | 151.16M | 162.89M | 145.35M | 199.74M |
| Total Debt | 533K | 894K | 51.62M | 372K | 825K |
| Net Debt | (76.71M) | (39.57M) | 42.57M | (54.05M) | (45.12M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $13.2M |
| Short-term Investments | $52.6M |
| Other Current | $2.3M |
| Total Current Assets | $68.2M |
| PP&E (Net) | $1.2M |
| Long-term Investments | $199.4M |
| Other Non-current | $48.0K |
| Total Non-current Assets | $200.7M |
| Total Assets | $268.8M |
Analysis
Selected assets total $268.8M for Latest. The largest visible component is Long-term Investments at $199.4M, about 74.2% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 |
How much cash does ORMP have?
Oramed Pharmaceuticals Inc. (ORMP) reported $45.95M in cash and equivalents in fiscal 2025.
How much debt does ORMP carry?
Oramed Pharmaceuticals Inc. (ORMP) reported $825,000.00 of total debt, with net debt of -$45.12M.
Continue the stock analysis
Jump to another research area for this company.